Disorder

SK Life Science Publishes Updated Real-World Experience on Cenobamate in Epilepsia Based on Recent 100,000 Patient Exposure Milestone

Retrieved on: 
Mittwoch, März 13, 2024
Pharmacist, ASM, Letter, Central nervous system, CNS, Ferrari, MD, MBA, Disorder, FDA, Food

The 100,000 unique patient exposure milestone is the result of increased adoption of cenobamate among epileptologists, general neurologists, and advanced practice providers in the U.S., Europe, Switzerland, the UK, Israel, and Canada.

Key Points: 
  • The 100,000 unique patient exposure milestone is the result of increased adoption of cenobamate among epileptologists, general neurologists, and advanced practice providers in the U.S., Europe, Switzerland, the UK, Israel, and Canada.
  • "Now that we have reached the milestone of 100,000 patient exposures, we have a richer set of data to understand patient experience with cenobamate," said Louis Ferrari, BS, RPh, MBA, Vice President of Medical Affairs at SK Life Science.
  • "This letter is intended to address how the clinical trials data relates to real-world experience."
  • To read the letter to the editor published by Epilepsia coauthored by Ferrari, William E. Rosenfeld, MD, and Marc Kamin, MD, please visit: https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17935.

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Retrieved on: 
Mittwoch, März 13, 2024
Taboo, Anxiety, Woman, Mental health, Ticker, Doctor of Philosophy, EAU, Neurostimulation, Urethra, MD, Pathology, Nursing, Quality of life, Female, Prostate, Urinary incontinence, Hope, Life, European, Health, Incontinence, Medtech, Patient, Disorder, Child, Male, European Association of Urology, Trial of the century, Ageing, Animation, Wound healing, Medical device

Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.

Key Points: 
  • Affluent Medical announces successful first-in-human implantation of its artificial sphincter Artus for the treatment of stress urinary incontinence.
  • This first implantation of the artificial urinary sphincter Artus was successfully performed by Prof. Roman Zachoval, MD, PhD, head of the Department of Urology at Thomayer University Hospital in Prague, Czech Republic, on a 68-year-old male with severe urinary incontinence.
  • “Artus is easy to prepare and implant due to its innovative design compared to the previous generation of urinary sphincters.
  • Artus is an implantable artificial urinary sphincter developed for the treatment of moderate to severe urinary incontinence in both men and women.

Genify Launches "Ghost", The Revolutionary Ghost - The First BTC NFT Collection Transferable to ERC20 Tokens

Retrieved on: 
Montag, März 11, 2024
Bitcoin, Ethereum, Collection, Light, Algorithm, NFTS, Sleep deprivation, Life, Non-fungible token, Perception, NFT, Death, ERC20, Disorder, Creativity, Ecosystem, Ghost, Uncertainty, Distortion, Music, BTC

Comprising 900 unique BTC NFTs, "Ghost" emerges as a pioneering collection from Genify, a leading platform for generative art on Bitcoin.

Key Points: 
  • Comprising 900 unique BTC NFTs, "Ghost" emerges as a pioneering collection from Genify, a leading platform for generative art on Bitcoin.
  • Through Eyesfi (the generative arts crosschain protocol developed by Genify), Ghost is first collection which is transferable from a BTC NFT into ERC20 Tokens.
  • Each Ghost NFT could be minted into 10,000 GHOST tokens on Abitrum, from the least efficient chain to the most efficient chain after the Dencun upgrade.
  • Genify is dedicated to creating NFT works for the BTC ecosystem with top-tier visual effects and artistic experiences.

SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe

Retrieved on: 
Donnerstag, März 7, 2024
Central nervous system, TEL, Patent, Cannabinoid, Safety, Disorder, Pharmaceutical industry

TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the process of granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations of cannabinoids and n-acylethanolamines (the “Patent”). The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.

Key Points: 
  • This patent covers combinations of cannabinoids and n-acylethanolamines (the “Patent”).
  • The Patent aligns seamlessly with the Company's proprietary technology designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.
  • The Patent was granted and validated in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United Kingdom.
  • This grant adds to the patent portfolio of the Company, thereby supporting the innovation of SciSparc’s technologies.

SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology

Retrieved on: 
Mittwoch, März 6, 2024
Central nervous system, Opioid, TEL, Pain, Patent, Chronic pain, Pain management, Patient, Disorder, Legislation, Pharmaceutical industry

The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.

Key Points: 
  • The Patent has been granted by the Canadian Intellectual Property Office, the government agency in Canada that administers intellectual property rights and legislation for patents.
  • "With the Canadian patent approval for our opioid reduction technology, SciSparc continues to build on global recognition of its innovations and breakthrough technologies.
  • We are all aware of how effective opiates are in relieving pain, but also for their addictive influence.
  • Our technology represents hope for safer and more effective pain management strategies worldwide," said SciSparc’s Chief Executive Officer, Oz Adler.

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

Retrieved on: 
Dienstag, März 5, 2024
Protein, Therapy, Patient, SVB Securities, Disorder, Keros, KROS, Conference

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 3:00 p.m. Eastern time.

Key Points: 
  • LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 3:00 p.m. Eastern time.
  • A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/leerink33/kros/2244432 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Retrieved on: 
Samstag, März 2, 2024
Sale, Exercise, Regulation D, Form, Form S-1, Disorder, Act, Addiction, Security (finance)

The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.

Key Points: 
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No.
  • The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses.
  • In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to 2,300,000 shares of common stock.
  • The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing

Retrieved on: 
Donnerstag, Februar 29, 2024
Central nervous system, Soroka Medical Center, TEL, Spectrum, ASD, Safety, Autism spectrum, Patient, Disorder, Clinical trial, Deviance (sociology), Pharmaceutical industry

TEL AVIV, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that it has successfully completed the manufacturing of and delivered its innovative SCI- 210 treatment, in accordance with its initiation of enrollment for the clinical trial at the Soroka Medical Center of pediatric patients who have Autism Spectrum Disorder ("ASD").

Key Points: 
  • "A clinical trial is a complicated project composed of many little steps- which in turn help ensure successful execution.
  • Having the clinical supply ready on site is the final step before first patient is administered treatment.
  • The clinical trial will rigorously examine the safety, tolerability, and efficacy of SCI- 210, in comparison to CBD monotherapy, for the treatment of ASD.
  • Designed as a randomized, double-blind, placebo-controlled clinical trial with cross-over, the clinical trial will span 20 weeks and enroll 60 children.

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

Retrieved on: 
Mittwoch, Februar 28, 2024
CFO, Bangladesh Technical Education Board, OTCQB, Pew, Research, NIH, Naltrexone, Risk, Prevalence, MUD, Disorder, CDC, Bupropion, Pharmaceutical industry

Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines.

Key Points: 
  • Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines.
  • MUD represents a significant public health concern, with devastating consequences for individuals, families, and communities across the country.
  • Despite the growing prevalence of MUD, effective treatment options remain limited, underscoring the urgent need for innovative approaches to address this complex and challenging condition.
  • Currently, there are no approved medications for MUD, and populations at risk of methamphetamine-involved overdose deaths are diversifying.

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mittwoch, Februar 28, 2024
Therapy, Research, Syndrome, Investment, Obesity, Technology transfer, Growth, KROS, PAH, Patient, Disorder, Protein, Ruxolitinib, Cytopenia, Orthostatic hypertension, Haematopoiesis, Keros, Pharmaceutical industry

Keros did not generate any revenue for the year ended December 31, 2022.

Key Points: 
  • Keros did not generate any revenue for the year ended December 31, 2022.
  • Research and development expenses were $37.5 million for the fourth quarter and $135.3 million for the year ended December 31, 2023, as compared to $24.9 million for the fourth quarter and $87.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $9.1 million for the fourth quarter and $34.8 million for the year ended December 31, 2023, as compared to $7.1 million and $27.5 million for the fourth quarter and year ended December 31, 2022.
  • Keros’ cash and cash equivalents as of December 31, 2023 was $331.1 million compared to $279.0 million as of December 31, 2022.